Abstract: The present invention provides a transdermal absorption preparation in which a drug-containing adhesive layer is formed on a support, the aforementioned adhesive layer contains at least a thermoplastic elastomer and a higher fatty acid ester, and a content of a tackifier is not more than 10 wt %, which is superior in drug solubility and releasability, as well as adhesiveness to the skin and low irritation to the skin.

Abstract: A percutaneous absorption preparation for the treatment of dementia wherein the drug-containing layer contains donepezil or a pharmaceutically acceptable salt thereof as an active ingredient and a stabilizer that is either (i) a mixture of a thiocyanate salt and a compound selected from the group consisting of tea catechin, (+)-catechin, epigallocatechin gallate, ascorbic acid, and isoascorbic acid, or (ii) a mixture of monothioglycerol and a compound selected from the group consisting of tea catechin, (+)-catechin, epigallocatechin gallate, and ascorbic acid is disclosed. The percutaneous absorption preparation meets the criteria of Procedure 1 and Procedure 2 of the U.S. Pharmacopoeia in short-term stress test (70° C. 48 hours storage), long-term accelerated test 1 (40° C. relative humidity 75% 1 month storage), and long-term accelerated test 2 (40° C. relative humidity 75% 3 months storage), and exhibits improved stability for long-term preservation.

Abstract: A percutaneous absorption preparation including donepezil for the treatment of dementia is disclosed. The percutaneous absorption preparation for the treatment of dementia includes a support layer, a drug-containing layer, and a release layer, wherein the drug-containing layer contains donepezil or a pharmaceutically acceptable salt thereof as an active ingredient; monothioglycerol, thiocyanate metal salt (preferably potassium salt) or dimethylthiourea as a stabilizer; and a pressure-sensitive adhesive. Also disclosed is a percutaneous absorption preparation for the treatment of dementia with reduced the formation of donepezil impurities.

Abstract: A percutaneous absorption preparation is disclosed. The percutaneous absorption preparation contains donepezil for treatment of dementia, wherein the preparation includes: (a) donepezil or its pharmaceutically acceptable salt as active component, (b) propylene glycol monocaprylate as solubilizer, and (c) styrene-isoprene-styrene block copolymer (“SIS”) as adhesive. The percutaneous absorption preparation has low skin irritation and high skin penetration.

Abstract: The present invention provides a patch containing an adhesive layer maintaining a drug, which is formed on a support, wherein the aforementioned adhesive layer comprises a thermoplastic elastomer, a non-volatile hydrocarbon oil in an amount exceeding 50 parts by weight and not more than 800 parts by weight per 100 parts by weight of the elastomer, and rivastigmine or a salt thereof, and the aforementioned adhesive layer optionally further contains a tackifier at a content in the adhesive layer of not more than 10 wt %.

Abstract: Provided is an adhesive sheet for adhesion to the skin, which has sufficient adhesiveness and causes low skin irritation. The adhesive sheet comprises a support and an adhesive layer formed on the support, in which the adhesive layer contains at least a thermoplastic elastomer and a non-volatile hydrocarbon oil. Further provided is a transdermal absorption preparation having sufficient adhesiveness and drug releaseability and causes low skin irritation. The transdermal absorption preparation comprises an adhesive sheet as described herein and a drug or a pharmaceutically acceptable salt thereof that is contained in the adhesive layer of the sheet.

Abstract: The invention provides an adhesive sheet for skin, which shows sufficient adhesiveness to the skin and causes low skin irritation. The adhesive sheet contains an adhesive layer formed on a support, in which the adhesive layer contains at least a thermoplastic elastomer, a non-volatile hydrocarbon oil, and polyisobutylene, but no tackifier. The polyisobutylene is a medium molecular weight polyisobutylene with a viscosity average molecular weight of more than 100,000 and not more than 500,000. The invention also provides a percutaneous absorption preparation containing a drug or a pharmaceutically acceptable salt thereof in an adhesive layer of the inventive adhesive sheet for skin.

Abstract: The present invention provides transdermal absorption preparation having a support, and a drug-containing adhesive layer formed on the support, wherein a drug-containing adhesive layer contains donepezil or a salt thereof, and a higher fatty acid salt.

Abstract: The present invention provides a transdermal absorption preparation in which a drug-containing adhesive layer is formed on a support, the aforementioned adhesive layer contains at least a thermoplastic elastomer and a higher fatty acid ester, and a content of a tackifier is not more than 10 wt %, which is superior in drug solubility and releasability, as well as adhesiveness to the skin and low irritation to the skin.

Abstract: A patch containing a storage layer retaining a drug or a pharmaceutically acceptable salt thereof and an adhesive layer which are formed on a support, wherein the adhesive layer contains a thermoplastic elastomer, and a non-volatile hydrocarbon oil in more than 50 parts by weight and not more than 800 parts by weight per 100 parts by weight of the elastomer, and the adhesive layer optionally further contains a tackifier at a content of not more than 10 wt %.

Abstract: The present invention provides transdermal absorption preparation having a support, and a drug-containing adhesive layer formed on the support, wherein a drug-containing adhesive layer contains donepezil or a salt thereof, and a higher fatty acid salt.

Abstract: The present invention provides an adhesive sheet for skin, which shows sufficient adhesiveness to the skin and causes low skin irritation. The first adhesive sheet for skin of the present invention has an adhesive layer formed on a support, wherein the aforementioned adhesive layer contains at least a thermoplastic elastomer, non-volatile hydrocarbon oil and polyisobutylene having a viscosity average molecular weight of more than 100,000 and not more than 500,000, and does not contain a tackifier.

Abstract: The present invention provides transdermal absorption preparation having a support, and a drug-containing adhesive layer formed on the support, wherein a drug-containing adhesive layer contains donepezil or a salt thereof, and a higher fatty acid salt.

Abstract: The present invention provides transdermal absorption preparation having a support, and a drug-containing adhesive layer formed on the support, wherein a drug-containing adhesive layer contains donepezil or a salt thereof, and a higher fatty acid salt.

Abstract: The invention provides a patch containing a support and, formed thereon, an adhesive layer retaining a drug. The adhesive layer contains a thermoplastic elastomer, a liquid component in an amount exceeding 300 parts by weight relative to 100 parts by weight of the elastomer, and risperidone or a salt thereof, and optionally a tackifier of not more than 10 wt %.

Abstract: The invention provides an adhesive sheet for adhesion to the skin, as well as a transdermal absorption preparation containing the adhesive sheet and a drug or a pharmaceutically acceptable salt thereof in the adhesive layer of the adhesive sheet. The adhesive sheet comprises a support and an adhesive layer formed on the support, wherein the adhesive layer contains at least a thermoplastic elastomer, and more than 300 parts by weight of liquid paraffin per 100 parts by weight of the elastomer, and wherein the adhesive layer contains not more than 10 wt % of a tackifier.

Abstract: The invention provides a transdermal absorption preparation showing sufficient adhesiveness on adhesion to the skin, causing low skin irritation, and capable of well controlling releaseability of lidocaine. The transdermal absorption preparation contains a support and an adhesive layer formed on the support. The adhesive layer contains a drug, as well as a thermoplastic elastomer, more than 300 parts by weight of liquid paraffin per 100 parts by weight of the elastomer, not more than 10 wt % of a tackifier, lidocaine, and an organic acid.